Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. (Q49064097)

18 February 2018

title

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. (English)

1 reference

18 February 2018

0 references

6

Vanmechelen E

1 reference

18 February 2018

Matthias Riemenschneider

1

object named as

Riemenschneider M

1 reference

18 February 2018

author name string

Schmolke M

2

1 reference

18 February 2018

Lautenschlager N

3

1 reference

18 February 2018

Guder WG

4

1 reference

18 February 2018

Vanderstichele H

5

1 reference

18 February 2018

Kurz A

7

1 reference

18 February 2018

language of work or name

English

0 references

publication date

1 April 2000

1 reference

18 February 2018

published in

Neuroscience Letters

1 reference

18 February 2018

volume

284

1 reference

18 February 2018

page(s)

85-88

1 reference

18 February 2018

issue

1-2

1 reference

18 February 2018

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900976-9

7 January 2021

10.1016/S0304-3940(00)00976-9

Identifiers

DOI

1 reference

18 February 2018

PubMed ID

10771168

1 reference

18 February 2018